Abstract
Systemic and topical targeted therapies are emerging as a rational approach to the management of skin cancers. In this article, we review the molecular pathways critical to the development of melanoma and the novel pharmacologic agents that have been rationally designed to target it. Included is a review of vemurafenib, imatinib, and ipilimumab for metastatic or unresectable melanoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
